
Liz Claman details a surprising turn in the weight loss drug market. Novo Nordisk has agreed to drop its patent infringement lawsuit against Hims & Hers and will now sell its Wegovy and Ozempic drugs through Hims & Hers' telehealth platform. This agreement has caused shares of Hims & Hers to soar by over 42%, while Novo Nordisk also sees a slight increase.